About Vyome Therapeutics
Vyome Therapeutics is a company based in Princeton (United States) founded in 2010. Vyome Therapeutics has raised $62.89 million across 7 funding rounds from investors including Iron Pillar, Perceptive Advisors and Aarin Capital. The company has 18 employees as of December 31, 2024. Vyome Therapeutics has completed 1 acquisition, including Oculo Health. Vyome Therapeutics offers products and services including Immuno-inflammatory Medicines. Vyome Therapeutics operates in a competitive market with competitors including Revance Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Princeton, United States
- Employees 18 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vyome Holdings, Inc.
-
Annual Revenue
$8.01 M (USD)-7.74as on Dec 31, 2024
-
Net Profit
-$7.13 M (USD)37.38as on Dec 31, 2024
-
EBITDA
-$6.65 M (USD)54.12as on Dec 31, 2024
-
Total Equity Funding
$62.89 M (USD)
in 7 rounds
-
Latest Funding Round
$22 M (USD), Series D
Jan 03, 2019
-
Investors
Iron Pillar
& 8 more
-
Employee Count
18
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vyome Therapeutics
Vyome Therapeutics is a publicly listed company on the NASDAQ with ticker symbol HIND in USA, operating in the Miscellaneous sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Vyome Therapeutics
Vyome Therapeutics offers a comprehensive portfolio of products and services, including Immuno-inflammatory Medicines.
Treatments targeting immuno-inflammatory conditions via clinical trials
People of Vyome Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Vyome Therapeutics
Vyome Therapeutics has successfully raised a total of $62.89M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $22 million completed in January 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vyome Therapeutics
Vyome Therapeutics has secured backing from 9 investors, including venture fund investors. Prominent investors backing the company include Iron Pillar, Perceptive Advisors and Aarin Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Growth capital provision and investment services for tech entrepreneurs across multiple locations.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Investments in early-stage technology companies are made by Kalaari Capital.
|
Locked | Locked | Locked |
Investor details for Vyome Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vyome Therapeutics
Vyome Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oculo Health.
Investment portfolio details for Vyome Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
AI-based eye tracking is utilized for brain health evaluation.
|
Locked | Locked | 2022 | Locked |
Complete acquisition details for Vyome Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Vyome Therapeutics
Detailed financials for Vyome Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vyome Therapeutics Comparisons
Peer comparison for Vyome Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vyome Therapeutics
Vyome Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
Detailed competitors of Vyome Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vyome Therapeutics
Complete news archive for Vyome Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vyome Therapeutics
Vyome Therapeutics was founded in 2010.
Vyome Therapeutics is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Vyome Therapeutics is a funded company, having raised a total of $62.89M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Vyome Therapeutics is 18.
Annual revenue of Vyome Therapeutics is $8.01M as on Dec 31, 2024.
Vyome Therapeutics was founded in 2010 and is headquartered in Princeton, United States. Small molecule-based therapeutics are developed by the company for immuno-inflammatory conditions. Lead candidates include VB-1953 gel, targeted at malignant fungating wounds and inflammatory acne, and VT1908, aimed at steroid-refractory uveitis. Additional applications cover rare immunological disorders such as arthritis, diabetes, psoriasis, Crohns disease, blindness, and lupus. Operations focus on advancing these treatments in the biopharmaceutical sector.
Vyome Therapeutics's top competitors include Revance Therapeutics, Annexon and MeiraGTx.
Vyome Therapeutics offers Immuno-inflammatory Medicines.
Yes, Vyome Therapeutics is publicly traded on NASDAQ under the ticker symbol HIND.
Vyome Therapeutics has made 1 acquisition, including Oculo Health.
Vyome Therapeutics has 9 investors. Key investors include Iron Pillar, Perceptive Advisors, Aarin Capital, Navam Capital, and Sabre Partners India.
The ticker symbol of Vyome Therapeutics is HIND on NASDAQ.
The valuation of Vyome Therapeutics is $25.03M as of Jul 2016.